Cellectar Biosciences Inc Share Price Nasdaq
Equities
US15117F2039
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | 44.27M 3.69B | Capitalization | 123M 10.23B |
---|---|---|---|---|---|
Net income 2024 * | -49M -4.09B | Net income 2025 * | -22M -1.84B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.77 x |
P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-5.93
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.19% |
Latest transcript on Cellectar Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 15/15/15 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 28/14/28 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 15/23/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 07/17/07 |
Douglas Swirsky
CHM | Chairman | 54 | 07/17/07 |
John Neis
BRD | Director/Board Member | 68 | 01/08/01 |
1st Jan change | Capi. | |
---|---|---|
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |